Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development and Validation of a Method for Simultaneous Estimation of Sitagliptin and Ertugliflozin in Rat Plasma by LC-MS method

Author(s): Pallepogu Venkateswara Rao*, Atmakuri Lakshmana Rao and Sahini Venkata Uma Maheswara Prasad

Volume 17, Issue 8, 2021

Published on: 30 June, 2020

Page: [1060 - 1074] Pages: 15

DOI: 10.2174/1573412916999200630123120

Price: $65

Abstract

Background: The development of sound bioanalytical LC-MS (liquid chromatography-mass spectroscopy) method(s) is of paramount importance during the process of drug discovery, development and culminating in a marketing approval. The use of oral antidiabetic agents has been increased significantly from the last decades and till now no bioanalytical method is available for quantitation of sitagliptin (SG) and ertugliflozin (EG) in biological matrix which can be applied to pharmacokinetic studies using LC-MS/MS.

Objective: To develop a new, rapid and sensitive LC-MS/MS method for the simultaneous estimation of sitagliptin (SG) and ertugliflozin (EG) in rat plasma by Liquid-Liquid Extraction method (LLE) using deutereated sitagliptin (SGd6) and ertugliflozin (EGd6).

Methods: Chromatographic separation was carried out on a reverse phase Waters, Xetrra C18 (150mm x 4.6mm, 2μm) column using a mixture of acetonitrile and OPA buffer (50:50v/v) at a flow rate of 1ml/min in isocratic mode. Quantification was achieved using an electrospray ion interface operating in positive mode, under Multiple Reaction Monitoring (MRM) conditions.

Results: The method showed excellent linearity over the concentration range of 5.00- 75.00pg/mL for sitagliptin and 0.75- 11.35pg/mL ertugliflozin. The intra-batch and inter batch precision (%CV) was ≤ 4.3% and matrix effect (%CV) was 0.02% and 0.12% for sitagliptin at HQC and LQC, respectively. Matrix effect (%CV) was 0.08% and 0.33% for ertugliflozin at HQC and LQC, respectively.

Conclusion: The simplicity of the method allows for application in laboratories, presents a valuable tool for pharmacokinetic studies. The particular assay has been proficiently put on pharmacokinetic study in rats subjects.

Keywords: Development, validation, sitagliptin, ertugliflozin, rat plasma, LC-MS/MS.

« Previous Next »
Graphical Abstract

[1]
Olokoba, A.B.; Obateru, O.A.; Olokoba, L.B. Type 2 diabetes mellitus: a review of current trends. Oman Med. J., 2012, 27(4), 269-273.
[http://dx.doi.org/10.5001/omj.2012.68] [PMID: 23071876]
[2]
Herman, G.A.; Stevens, C.; Van Dyck, K.; Bergman, A.; Yi, B.; De Smet, M.; Snyder, K.; Hilliard, D.; Tanen, M.; Tanaka, W.; Wang, A.Q.; Zeng, W.; Musson, D.; Winchell, G.; Davies, M.J.; Ramael, S.; Gottesdiener, K.M.; Wagner, J.A. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin. Pharmacol. Ther., 2005, 78(6), 675-688.
[http://dx.doi.org/10.1016/j.clpt.2005.09.002] [PMID: 16338283]
[3]
Herman, G.A.; Bergman, A.; Liu, F.; Stevens, C.; Wang, A.Q.; Zeng, W.; Chen, L.; Snyder, K.; Hilliard, D.; Tanen, M.; Tanaka, W.; Meehan, A.G.; Lasseter, K.; Dilzer, S.; Blum, R.; Wagner, J.A. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J. Clin. Pharmacol., 2006, 46(8), 876-886.
[http://dx.doi.org/10.1177/0091270006289850] [PMID: 16855072]
[4]
Vincent, S.H.; Reed, J.R.; Bergman, A.J.; Elmore, C.S.; Zhu, B.; Xu, S.; Ebel, D.; Larson, P.; Zeng, W.; Chen, L.; Dilzer, S.; Lasseter, K.; Gottesdiener, K.; Wagner, J.A.; Herman, G.A. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab. Dispos., 2007, 35(4), 533-538.
[http://dx.doi.org/10.1124/dmd.106.013136] [PMID: 17220239]
[5]
Miao, Z.; Nucci, G.; Amin, N.; Sharma, R.; Mascitti, V.; Tugnait, M.; Vaz, A.D.; Callegari, E.; Kalgutkar, A.S. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab. Dispos., 2013, 41(2), 445-456.
[http://dx.doi.org/10.1124/dmd.112.049551] [PMID: 23169609]
[6]
Dendup, T. Feng, X Environmental Risk Factors for Developing Type 2 Diabetes Mellitus A Systematic Review. Int. J. Environ. Res. Public Health, 2018, 15(1)
[7]
Krentz, A.J.; Bailey, C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs, 2005, 65(3), 385-411.
[http://dx.doi.org/10.2165/00003495-200565030-00005] [PMID: 15669880]
[8]
Marcum, Z.A.; Vande Griend, J.P.; Linnebur, S.A. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am. J. Geriatr. Pharmacother., 2012, 10(4), 264-271.
[http://dx.doi.org/10.1016/j.amjopharm.2012.05.002] [PMID: 22683398]
[9]
Sirtori, C.R.; Franceschini, G.; Galli-Kienle, M.; Cighetti, G.; Galli, G.; Bondioli, A.; Conti, F. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin. Pharmacol. Ther., 1978, 24(6), 683-693.
[http://dx.doi.org/10.1002/cpt1978246683] [PMID: 710026]
[10]
Xiaonian, H.; Wang, J. Huang, J; Peng, L. Pharmacokinetic Study of Janumet (Sitagliptin and Metformin) Tablets by LC-MS/MS Coupled with Ion-Pair Solid Phase Extraction. Curt. Pha. Anal., 2019, 15, 776.
[http://dx.doi.org/10.2174/1573412914666181011141714]
[11]
Ramalingam, P.; Bhaskar, V.U.; Reddy, Y.P.; Kumar, K.V.U.; Reddy, Y.P.; Kumar, K.V. Stability-indicating RP-HPLC method for the simultaneous determination of sitagliptin and simvastatin in tablets. Indian J. Pharm. Sci., 2014, 76(5), 407-414.
[PMID: 25425754]
[12]
Reddy, S.; Ahmed, I.; Ahmad, I.; Mukhopadhyay, A.; Thangam, S. Development and validation of a method for simultaneous estimation of metformin and sitagliptin in human plasma by LC-MS-MS and its application in a bioequivalence study. J. Chromatogr. Sci., 2015, 53(9), 1549-1556.
[http://dx.doi.org/10.1093/chromsci/bmv055] [PMID: 25987553]
[13]
Swales, J.G.; Gallagher, R.T.; Denn, M.; Peter, R.M. Simultaneous quantitation of metformin and sitagliptin from mouse and human dried blood spots using laser diode thermal desorption tandem mass spectrometry. J. Pharm. Biomed. Anal., 2011, 55(3), 544-551.
[http://dx.doi.org/10.1016/j.jpba.2011.02.030] [PMID: 21435813]
[14]
Maryam, M.; Reza, M.D. Sohrabi; Mortazavinik, S. Using Gold Nanoparticles for Ultra-trace Spectro photometric Determination of Sitagliptin Drug in Various Real Samples. Curt. Pha. Anal., 2020, 16, 1.
[15]
Ramji, R.; Ali, F. Chandra, A; Kumar, R; Meenakshi, D; Gyanendra, N.S. Simultaneous Determination of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin in Bulk Drug and Formulation by UPLC Q-TOF-MS. Curt. Pha. Anal., 2019, 15, 1.
[16]
Sena, C.; Armagan, O. Toker, S. Determination of Sitagliptin with Fluorescamine in Tablets and Spiked Serum Samples by Spectrofluorimetry and a Degradation Study. Curt. Pha. Anal., 2012, 8, 278.
[http://dx.doi.org/10.2174/157341212801619270]
[17]
Aline, R.; Leila, S.D.; Ana Isa, P.M.; Cristiane, F.C.; Andrea, I.A.; Clarice Madalena, B.R. A simple stability indicating LC-UV method to assay sitagliptin phosphate in tablets. Curt. Pha. Anal., 2012, 8, 569.
[18]
Marwa, F.; Ali, B. Noha, N; Atia. Sensitive Spectrofluorimetric Methods for Determination of Sitagliptin Phosphate, Dipeptidyl Peptidase-4 Inhibitor, in Pharmaceutical Tablets and Spiked Human Urine. Curt. Pha. Anal., 2018, 14, 483.
[http://dx.doi.org/10.2174/1573412913666170906164249]
[19]
Abbas Moussa, B.; Mahrouse, M.A.; Fawzy, M.G. A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers. J. Pharm. Biomed. Anal., 2019, 163, 153-161.
[http://dx.doi.org/10.1016/j.jpba.2018.09.052] [PMID: 30312887]
[20]
Rao, Z.; Ma, Y.R.; Qin, H.Y.; Wang, Y.F.; Wei, Y.H.; Zhou, Y.; Zhang, G.Q.; Wang, X.D.; Wu, X.A. Development of a LC-MS/MS method for simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in rat plasma: application to the herb-drug interaction study of metoprolol and breviscapine. Biomed. Chromatogr., 2015, 29(9), 1453-1460.
[http://dx.doi.org/10.1002/bmc.3445] [PMID: 25753317]
[21]
Bae, S.H.; Lee, J.K.; Cho, D.Y.; Bae, S.K. Simultaneous determination of metoprolol and its metabolites, α-hydroxymetoprolol and O-desmethylmetoprolol, in human plasma by liquid chromatography with tandem mass spectrometry: Application to the pharmacokinetics of metoprolol associated with CYP2D6 genotypes. J. Sep. Sci., 2014, 37(11), 1256-1264.
[http://dx.doi.org/10.1002/jssc.201301353] [PMID: 24648255]
[22]
Zhang, L.; Tian, Y.; Zhang, Z.; Chen, Y. Simultaneous determination of metformin and rosiglitazone in human plasma by liquid chromatography/tandem mass spectrometry with electrospray ionization: application to a pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 854(1-2), 91-98.
[23]
Marques, M.A. Soares, Ade.S.; Pinto, O.W.; Barroso, P.T.; Pinto, D.P.; Ferreira-Filho, M.; Werneck-Barroso, E. Simple and rapid method determination for metformin in human plasma using high performance liquid chromatography tandem mass spectrometry: application to pharmacokinetic studies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 852(1-2), 308-316.
[http://dx.doi.org/10.1016/j.jchromb.2007.01.030] [PMID: 17331818]
[24]
Alini, D.C. Lange; Franciele, T.G; Carolina dos, S.P; Vitor, T; Nadia, M.V; Elfrides Eva, S.S. Stability-Indicating LC Assay with Determination of System Suitability Limits by a Robustness Test for Sitagliptin in Tablets and Assessment of Cytotoxicity for Degradation Products. Curt. Pha. Anal., 2012, 8, 360.
[http://dx.doi.org/10.2174/157341212803341645]
[25]
Shaolian, Z.; Qi, S. Yong, T; Weng, N. Critical Review of Development, Validation, and Transfer for High Throughput Bioanalytical LCMS/MS Method. Curt. Pha. Anal., 2005, 1, 3.
[http://dx.doi.org/10.2174/1573412052953346]
[26]
Tiwari, G.; Tiwari, R. Bioanalytical method validation: An updated review. Pharm. Methods, 2010, 1(1), 25-38.
[http://dx.doi.org/10.4103/2229-4708.72226] [PMID: 23781413]
[27]
Meesters; Roland; Voswinkel; Stephan. Bioanalytical Method Development and Validation: from the USFDA 2001 to the USFDA 2018 Guidance for Industry. Journal of Applied Bioanalysis., 2018, 4, 67-73.
[http://dx.doi.org/10.17145/jab.18.010]
[28]
U.S. Department of health and human sciences. Food Drug Administration, Guidance for industry, Bioanalytical method development and validation. US. Food Drug Administration, Center for Drug Evaluation and Research, 2001. http://www.fda.gov/downloads/GuidenceCompliance Information/Guidence/UCM073384

Rights & Permissions Print Cite
Article Metrics
41
1
© 2024 Bentham Science Publishers | Privacy Policy